YCBD - cbdMD announces collaboration to study its cannabinoid blend on dogs with osteoarthritis

cbdMD ([[YCBD]] -2.2%) says its recently formed subsidiary, cbdMD Therapeutics has started a collaboration with the researchers at the Colorado State University ((CSU)) veterinary program to assess the effects of proprietary cbdMD branded cannabinoid blend on dogs with osteoarthritis.The study expected to be complete by spring 2022 “will provide validating data on the efficacy of the Company's products in reducing pain and improving joint mobility in dogs,” cbdMD said.“Our partnership with CSU will serve as the foundation for future work where we will explore the clinical impact of our proprietary broad spectrum cannabinoid blend on pain and mobility in our pets,” noted Martin Sumichrast, the Co-CEO of cbdMD.In mid-March, cbdMD announced the formation of its subsidiary, cbdMD Therapeutics with former FDA official Sibyl Swift acting as a co-chair of the company.

For further details see:

cbdMD announces collaboration to study its cannabinoid blend on dogs with osteoarthritis